Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces October 6 Webcast of Presentation at the JMP Securities 3rd Annual Healthcare Focus Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (Nasdaq:EXEL) announced today that George A.
Scangos, PhD, President and Chief Executive Officer of Exelixis, will
present at the JMP Securities 3rd Annual Healthcare Focus Conference
at 11:30 a.m. ET/8:30 a.m. PT on Monday, October 6, 2008. Dr. Scangos
will discuss updates to the company's development pipeline and
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors on the Exelixis website at
Exelixis, Inc. is a development-stage biotechnology company
dedicated to the discovery and development of novel small molecule
therapeutics for the treatment of cancer and other serious diseases.
The company is leveraging its fully integrated drug discovery platform
to fuel the growth of its development pipeline, which is primarily
focused on cancer. Currently, Exelixis' broad product pipeline
includes investigational compounds in phase 3, phase 2, and phase 1
clinical development. Exelixis has established strategic corporate
alliances with major pharmaceutical and biotechnology companies,
including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth
Pharmaceuticals, and Daiichi-Sankyo. For more information, please
visit the company's web site at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
Source: Exelixis, Inc.